|
Neuralgia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
In the meta-analysis, polymorphisms in HLA-DRB1*13 (odds ratio [OR], 2.96; confidence interval [CI], 1.93-4.56), HLA-DRB1*04 (OR, 1.40; CI, 1.02-1.93), HLA-DQB1*03 (OR, 2.86; CI, 1.57-5.21), HLA-A*33 (OR, 2.32; CI, 1.42-3.80), and HLA-B*44 (OR, 3.17; CI, 2.22-4.55) were associated with significantly increased risk of developing NP, whereas HLA-A*02 (OR, 0.64; CI, 0.47-0.87) conferred reduced risk and neither rs1799971 in OPRM1 (OR, 0.55; CI, 0.27-1.11) nor rs4680 in COMT (OR, 0.95; CI, 0.81-1.13) were significantly associated with NP.
|
29351172 |
2018 |
|
Respiratory Tract Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings are in concordance with previously observed differential CTL activation, caused by variation at extra-epitopic residues, and may reflect an immune adaptation strategy of human influenza viruses that allows them to cope with potent CTL immunity to the M1<sub>58-66</sub> epitope in HLA-A*0201-positive individuals, resulting in increased virus replication and shedding and possibly increasing disease severity.<b>IMPORTANCE</b> Influenza viruses are among the leading causes of acute respiratory tract infections.
|
29593036 |
2018 |
|
Seizures
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
<i>HLA-A*31:01</i> and Oxcarbazepine-Induced DRESS in a Patient With Seizures and Complete <i>DCX</i> Deletion.
|
29610167 |
2018 |
|
Cholestatic hepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.
|
30138689 |
2018 |
|
Tuberculosis, Multidrug-Resistant
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We determined the high-resolution allele and haplotype frequencies at the human leucocyte antigen (HLA)A, B and DRB1 loci in the Han population of Hubei province, the TB endemic area of Central China, with pulmonary tuberculosis (PTB), and established the relationship between HLA-A, B and DRB1 alleles as well as haplotypes and susceptibility to multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB).
|
29219243 |
2018 |
|
Childhood Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SLL TCR T cells efficiently killed medulloblastoma HLA-A*02<sup>+</sup> DAOY cells as well as primary HLA-A*02<sup>+</sup> medulloblastoma cells.
|
29615432 |
2018 |
|
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SLL TCR T cells efficiently killed medulloblastoma HLA-A*02<sup>+</sup> DAOY cells as well as primary HLA-A*02<sup>+</sup> medulloblastoma cells.
|
29615432 |
2018 |
|
Acute viral encephalitis
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Subjects with acute viral encephalitis in comparison to subjects without acute viral encephalitis showed a significantly higher frequency of 2DL1 KIR gene and AA KIR haplotypes and of HLA-C2 and HLA-A-Bw4 alleles.
|
29707126 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.010 |
Biomarker
|
disease |
BEFREE |
To investigate whether smoking in patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon beta (IFN-β) is associated with the relapse rate and whether there is an interaction between smoking and human leukocyte antigen (HLA)-DRB1*15:01, HLA-A*02:01, and the N-acetyltransferase-1 (<i>NAT1</i>) variant rs7388368A.
|
29343473 |
2018 |
|
Psychotic symptom
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
HLA-A*02~B*57~Cw*06~DRB1*07~DQB1*09 and HLA-A*02~B*08~Cw*07 are associated with rapid cycling (pc = 1.9 × 10<sup>-3</sup> and 1.05 × 10<sup>-2</sup> , respectively); (iii) the 8.1AH-derived HLA class II-DRB*03~HLA-DQB1*02 sub-haplotype is more frequent in BD patients with a history of suicidal behaviors (pc = 2.1 × 10<sup>-2</sup> ); and (iv) disease onset by an hypomanic episode or by psychotic symptoms are, respectively, more frequent in BD patients bearing the 7.1 AH-derived A*03~B*07~DRB1*15 sub-haplotype (pc = 8.5 × 10<sup>-3</sup> ) and the HLA-A*02~B*07~DRB1*15 sub-haplotype (pc = 4.0 × 10<sup>-2</sup> ).
|
29869414 |
2018 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
We randomly assigned HLA-A*02:01- or HLA-A*24:02-positive patients with advanced PDAC to receive GEMWT1 or GEM.
|
29358173 |
2018 |
|
Acute myeloid leukemia with mutated NPM1
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We compared HLA class I distribution in NPMc+ AML patient cohort (398 patients from 5 centers) with the HLA allele frequencies of the healthy population and found HLA-A*02, B*07, B*40 and C*07 underrepresented in the NPMc+ AML group.
|
30557403 |
2018 |
|
Congenital atresia of extrahepatic bile duct
|
0.010 |
Biomarker
|
disease |
BEFREE |
We previously reported that an association of maternal microchimerism (MMc) in BA and a significant compatibility of HLA-A between the patient with BA and their mother.
|
30006139 |
2018 |
|
Merkel cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
HLA-A*02:01/KLL tetramer<sup>+</sup> CD8<sup>+</sup> T cells from MCC patient peripheral blood mononuclear cells (PBMC) and tumor-infiltrating lymphocytes (TIL) were isolated via flow cytometry.
|
28093446 |
2017 |
|
Carcinoma, Transitional Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thirty eight HLA-A*24:02-positive patients with progressive UC were enrolled in this study.
|
27998971 |
2017 |
|
Chikungunya Fever
|
0.010 |
Biomarker
|
disease |
BEFREE |
Complex antigen presentation pathway for an HLA-A*0201-restricted epitope from Chikungunya 6K protein.
|
29084215 |
2017 |
|
Fatigue
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Prevalences of female sex; chronic fatigue; IC; and HLA-A*29, B*44 positivity were greater in patients with fibromyalgia.
|
28422000 |
2017 |
|
Fibromyalgia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Prevalences of female sex; chronic fatigue; IC; and HLA-A*29, B*44 positivity were greater in patients with fibromyalgia.
|
28422000 |
2017 |
|
Hemorrhagic Fever with Renal Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Novel Identified HLA-A*0201-Restricted Hantaan Virus Glycoprotein Cytotoxic T-Cell Epitopes Could Effectively Induce Protective Responses in HLA-A2.1/K<sup>b</sup> Transgenic Mice May Associate with the Severity of Hemorrhagic Fever with Renal Syndrome.
|
29312318 |
2017 |
|
Malaria, Falciparum
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In addition to relevant signatures of populations' demography and migrations history in the genetic differentiation patterns of both HLA-A and -B loci, we found that the frequencies of three HLA alleles, B*53, B*78 and A*74, were significantly associated with Plasmodium falciparum malaria prevalence, suggesting their increase through pathogen-driven selection in malaria-endemic environments.
|
28950417 |
2017 |
|
Scrub Typhus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we identified HLA-A*0201-restricted and highly conserved CD8 T-cell epitopes in the TSA56 antigen, which may be valuable tools for assessing cellular immunity against O. tsutsugamushi and developing an effective scrub typhus vaccine.
|
29259327 |
2017 |
|
Superinfection
|
0.010 |
Biomarker
|
group |
BEFREE |
HLA-A*29 (hazard ratio, 4.10; 95% CI, 0.88-14.76; P = 0.069), HLA-B*35 (hazard ratio, 4.64; 95% CI, 1.33-18.17; P = 0.017), HLA-C*04 (hazard ratio, 5.30; 95% CI, 1.51-20.77; P = 0.010), HLA-C*16 (hazard ratio, 4.05; 95% CI, 0.87-14.62; P = 0.071), HLA-DRB1*07 (hazard ratio, 3.29; 95% CI, 0.94-12.90; P = 0.062) and HLA-DRB1*08 (hazard ratio, 15.37; 95% CI, 2.11-79.80; P = 0.011) were associated with an increased risk of superinfection at α = 0.10, whereas HLA-DRB1*11 was associated with decreased superinfection risk (hazard ratio, 0.13; 95% CI, 0.00-1.03; P = 0.054).
|
28244954 |
2017 |
|
Varicella zoster
|
0.010 |
Biomarker
|
disease |
BEFREE |
CMV B35/IPS CD8<sup>+</sup> T cells cross-reacted with HLA-B51 and/or HLA-B58/B57 (23% of tetramer-positive individuals), FLU A2/GIL (influenza IMP[58-66] HLA-A*02:01/GILGFVFTL) CD8<sup>+</sup> T cells with HLA-B38 (90% of tetramer-positive individuals), and VZV A2/ALW (varicella zoster virus IE62[593-601] HLA-A*02:01/ALWALPHAA) CD8<sup>+</sup> T cells with HLA-B55 (two unrelated individuals).
|
28332333 |
2017 |
|
Hormone refractory prostate cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Twelve patients having HLA-A*2402 with CRPC after failure of docetaxel chemotherapy were enrolled.
|
28498618 |
2017 |
|
Urothelial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thirty eight HLA-A*24:02-positive patients with progressive UC were enrolled in this study.
|
27998971 |
2017 |